Glenmark Pharmaceuticals has received the final USFDA approval for its generic oral contraceptive norgestimate ethinyl estradiol tablets. in strengths of 0.18 mg/0.025 mg, 0.215 mg/ 0.025 mg and 0.25 mg/0.025mg. The drug is a generic version of Ortho Tri-cyclen Lo tablets of Janssen Pharmaceuticals, Inc. The estimated market size of Ortho Tricyclen Lo tablets is around $503.9 million. The company’s current portfolio consists of 107 products authorised for distribution in the US marketplace and 62 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.
Company Profile : Glenmark Pharma Ltd
Leave a Reply